StockData
Zai Lab Ltd logo

Zai Lab Ltd (ZLAB) company profile

ZLABNasdaqPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 7/30421% above fair value
$23.53+0.06 (+0.26%)

Close on Nov 17, 2026Market cap $3.65BP/E –Yield –

About Zai Lab

Pharmaceutical Preparations, SIC 2834

Zai Lab is a commercial-stage biopharmaceutical company that develops and commercializes therapies for oncology, autoimmune disorders, neuroscience, and infectious diseases. Its commercial portfolio features licensed therapies including ZEJULA for ovarian cancer, VYVGART and VYVGART Hytrulo for generalized myasthenia gravis and chronic inflammatory demyelinating polyneuropathy, NUZYRA for pneumonia and skin infections, and OPTUNE for glioblastoma. The company also markets QINLOCK for gastrointestinal stromal tumors, XACDURO for hospital-acquired bacterial infections, and AUGTYRO for solid tumors and non-small cell lung cancer. Its customers include medical centers, distributors, and adult patients requiring specialized treatments.

Geographically, the company maintains operations in Greater China and the United States, with commercial sales teams covering major medical centers in mainland China, Hong Kong, Macau, and Taiwan. The business operates seven approved commercial programs alongside internal research and development activities and clinical trial collaborations across China and the United States. The provided text does not state the location of its corporate headquarters.

Summary of the business section of Zai Lab's latest annual report, written by StockData.

Company profile

Company

Legal name
Zai Lab Ltd
Headquarters
Shanghai, China
Address
899 Halei Road, Building B, Pudong
Phone
862161632588
Employees
1,784, Dec 31, 2025
Industry
Pharmaceutical Preparations
Incorporated in
E9
Fiscal year ends
December 31
Auditor
KPMG LLP, Short Hills, New Jersey

Stock & identifiers

Ticker
ZLAB
Exchange
Nasdaq
IPO date
Sep 21, 2017
Shares outstanding
1.55B, Jul 31, 2026
Public float
$3.80B, Jun 30, 2025
Filer category
Large accelerated filer
Stock splits
10-for-1, Mar 30, 2022
SEC CIK
1704292
CUSIP
98887Q104
ISIN
US98887Q1040
FIGI
BBG00HFX3N90
Share class FIGI
BBG00HFX3P04
LEI
549300P2UYQ9U5LY1T58
EIN
00-0000000

Executives and directors

Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years

NamePositionShares owned
Ying DuChairperson & CEO, Director1,226,224
Yajing ChenChief Financial Officer36,240
Frazor Titus Edmondson IIIChief Legal Officer30,346
Yizhe WangOperating Partner–
Joshua L. SmileySee Remarks117,602
Rafael AmadoSee Remarks57,022
Richard GaynorDirector81,965
William LisDirector41,931
Michel VounatsosDirector72,787
Scott W. MorrisonDirector56,904
John D. DiekmanDirector122,140
Leon O. Moulder JrDirector94,973
Peter WirthDirector420,121
Nisa LeungDirector8,019,229
Kai-Xian ChenDirector39,525

CEO pay and shareholder return

Pay versus performance table from the proxy statement

Fiscal yearCEO total payCEO pay actually paidOther executives (avg)Value of $100 investedPeer group
FY2025$10.68M$1.86M$3.80M$13$125
FY2024$9.08M$12.07M$3.62M$19$93
FY2023$12.04M$7.52M$3.89M$20$94
FY2022$20.21M$739.60K$6.84M$23$90
FY2021$15.32M-$30.50M$6.18M$46$100
FY2020$8.54M$112.74M$3.40M$325$126

“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.

Executive compensation, fiscal 2025

Summary compensation table from the latest proxy statement

ExecutiveSalaryStock awardsOption awardsIncentive payOtherTotalvs. prior year
Samantha (Ying) Du
Chief Executive Officer and Chairperson of the Board of Directors
$908.73K$3.23M$5.82M$695.18K$17.50K$10.68M+18%
Yajing Chen
Chief Financial Officer
$520.00K$1.21M$1.23M$205.92K$17.50K$3.19M+21%
Rafael Amado
President, Head of Global Research and Development
$641.70K$1.51M$1.54M$298.39K$17.50K$4.01M+10%
F. Ty Edmondson
Chief Legal Officer and Corporate Secretary
$590.88K$1.21M$1.23M$233.99K$17.50K$3.28M+19%
Josh Smiley
President and Chief Operating Officer
$672.75K$1.81M$1.85M$347.14K$17.50K$4.70M-14%

Stock and option awards are grant-date fair values, not realized pay. “Other” includes pension value changes and all other compensation. Source proxy statement.

IPO

From the final prospectus (Form 424B4) and the first day of trading

Offering

Type
Initial public offering
Final prospectus filed
Sep 21, 2017
Offer price
$18.00
Securities offered
8,333,333
Gross proceeds
$150.00M
Exchange
Nasdaq
First trading day
Sep 20, 2017
Lock-up ends (est.)
Mar 19, 2018

“The initial public offering price is $18.00 per ADS.”

Lock-up end is estimated as 180 days after the first trading day; the prospectus sets the actual terms.

Employees

Headcount reported in annual reports

“As of January 31, 2026, we had 1,784 full-time employees, of which 1,710 were located in Greater China.”

Corporate history

Events identified from SEC filings

See a number that looks wrong?